References
Akinyemi, K. O., B. S. Bamiro and A. O. Coker, 2007: Salmonellosis in Lagos, Nigeria: incidence of Plasmodium falciparum-associated co-infection, patterns of antimicrobial resistance, and emergence of reduced susceptibility to fluoroquinolones. Journal of health, population, and nutrition, 25, 351-358.
Brink, A. J., 2019: Epidemiology of carbapenem-resistant Gram-negative infections globally. Current opinion in infectious diseases, 32, 609-616.
CLSI, 2011: Clinical and Laboratory Standards Institute. Performanc Standardsfor Antimicrobial Susceptibility Testing. Nineteenth Informational Supplement. CLSI document M100-S21. Wayne, PA, USA.
Falagas, M. E., D. E. Karageorgopoulos and P. Nordmann, 2011: Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future microbiology, 6, 653-666.
Founou, L. L., R. C. Founou, M. Allam, A. Ismail, C. F. Djoko and S. Y. Essack, 2018: Genome Sequencing of Extended-Spectrum beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae Isolated from Pigs and Abattoir Workers in Cameroon. Frontiers in microbiology, 9, 188.
Hertz, F. B., F. Jansaker, K. O. Okon, I. S. Abdulmumin, J. O. Onah, J. Ladan and J. D. Knudsen, 2019: ESBL-production in Escherichia coli and Klebsiella pneumoniae isolates from Nigeria.MicrobiologyOpen, 8, e00816.
Landman, D., J. K. Salvani, S. Bratu and J. Quale, 2005: Evaluation of techniques for detection of carbapenem-resistant Klebsiella pneumoniae in stool surveillance cultures. Journal of clinical microbiology,43, 5639-5641.
Muller-Schulte, E., M. N. Tuo, C. Akoua-Koffi, F. Schaumburg and S. L. Becker, 2019: High prevalence of ESBL-producing Klebsiella pneumoniae in clinical samples from central Cote d’Ivoire.International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases .
Obasi, A., S. Nwachukwu, E. Ugoji, C. Kohler, A. Gohler, V. Balau, Y. Pfeifer and I. Steinmetz, 2017: Extended-Spectrum beta-Lactamase-Producing Klebsiella pneumoniae from Pharmaceutical Wastewaters in South-Western Nigeria. Microbial drug resistance (Larchmont, N.Y.), 23, 1013-1018.
Olalekan, A., F. Onwugamba, B. Iwalokun, A. Mellmann, K. Becker and F. Schaumburg, 2019: High proportion of carbapenemase producing Escherichia coli and Klebsiella pneumonia e among extended spectrum beta-lactamase producers in Nigerian hospitals. Journal of global antimicrobial resistance .
Pai, H., S. Lyu, J. H. Lee, J. Kim, Y. Kwon, J. W. Kim and K. W. Choe, 1999: Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae : prevalence of TEM-52 in Korea. Journal of clinical microbiology, 37, 1758-1763.
Phillips, I., 1993: Cowan and Steel’s Manual for the Identification of Medical Bacteria. J Clin Pathol, 46, 975-975.
Raji, M. A., W. Jamal, O. Ojemhen and V. O. Rotimi, 2013: Point-surveillance of antibiotic resistance in Enterobacteriaceaeisolates from patients in a Lagos Teaching Hospital, Nigeria.Journal of infection and public health, 6, 431-437.
Ranjbar, R., A. Fatahian Kelishadrokhi and M. Chehelgerdi, 2019: Molecular characterization, serotypes and phenotypic and genotypic evaluation of antibiotic resistance of the Klebsiella pneumoniaestrains isolated from different types of hospital-acquired infections.Infection and drug resistance, 12, 603-611.
Rossolini, G. M., 2015: Extensively drug-resistant carbapenemase-producing Enterobacteriaceae : an emerging challenge for clinicians and healthcare systems. Journal of internal medicine, 277, 528-531.
Sturenburg, E., A. Kuhn, D. Mack and R. Laufs, 2004: A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance.The Journal of antimicrobial chemotherapy, 54, 406-409.
Yigit, H., A. M. Queenan, G. J. Anderson, A. Domenech-Sanchez, J. W. Biddle, C. D. Steward, S. Alberti, K. Bush and F. C. Tenover, 2001: Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.Antimicrobial agents and chemotherapy, 45, 1151-1161.
Table 1: Numbers and types of collected samples and K. pneumoniae positive isolates that have been used in the current study distributed in relation to the source of sampling.